Home > Oncology > ASCO 2020 > COVID-19 & Telemedicine > Thoracic cancers versus COVID-19

Thoracic cancers versus COVID-19

Presented By
Leora Horn, Vanderbilt-Ingram Cancer Center, USA
Conference
ASCO 2020
Trial
TERAVOLT
Featured video: Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. https://vimeo.com/440623327 In the global Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, 428 thoracic cancer patients infected with COVID-19 have been followed up, and the data are concerning. So far, 169 have recovered, 119 have ongoing COVID-19 infection, but 141 have died. Prof. Leora Horn (Vanderbilt Ingram Cancer Center, USA) presented the results [1]. "Patients with thoracic malignancies are considered high-risk given their age, pre-existing comorbidities, smoking, and pre-existing lung damage in addition to therapies administered to treat their illness. We launched a global consortium to collect data on patients with thoracic malignancies diagnosed with COVID-19 infection to understand the impact on this patient population," she said. Among ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on